Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial
- PMID: 23485720
- DOI: 10.1159/000346083
Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial
Abstract
Background and aims: Upper gastrointestinal bleeding (UGB) is an important precipitating factor for the development of hepatic encephalopathy (HE) in cirrhotic patients. The aim of this study was to evaluate the efficacy of lactulose in a controlled randomized trial for prophylaxis of HE after UGB.
Patients and methods: 128 cirrhotic patients with UGB were consecutively classified according to Child-Pugh criteria and randomized to receive lactulose (group A, n = 63) or no lactulose (group B, n = 65) treatment after the symptoms of active bleeding disappeared. Curative effects were observed for 6 days.
Results: Two patients in group A and 11 in group B had developed HE; the incidence rates were 3.2 and 16.9% (χ(2) 5.2061, p < 0.05). After treatment, a significant increase in ammonia level and higher number connection test (NCT) in the non-lactulose group, median blood ammonia levels (60.0 vs. 52.0), p < 0.05, and median NCT (43 vs. 38), p < 0.05, were observed. Patients who had developed HE had a significantly higher baseline Child-Turcotte-Pugh score (10.15 ±1.82 vs. 6.35 ± 1.60, p < 0.05), alanine aminotransferase (111.25 ± 91.62 vs. 48.32 ± 47.45, p < 0.05), aspartate aminotransferase (171.42 ± 142.68 vs. 46.33 ± 42.68, p < 0.05), total bilirubin (73.44 ± 47.20 vs. 29.75 ± 22.08, p < 0.05), serum albumin (24.65 ± 5.04 vs. 33.43 ± 6.49, p < 0.05), plasma prothrombin time (22.18 ± 4.60 vs. 17.12 ± 4.62, p < 0.05), and lower hemoglobin level (72.31 ± 15.15 vs. 87.45 ± 19.79, p < 0.05) as compared to patients who did not develop HE. On unconditional logistic regression analysis, patients who had developed HE were significantly associated with a higher baseline Child-Turcotte-Pugh score (OR 9.92, 95% CI 1.94-50.63, p < 0.05) and lactulose therapy (OR 0.02, 95% CI 0-0.74, p < 0.05) but were not associated with other parameters.
Conclusions: Lactulose is an effective prophylaxis agent of HE for cirrhotic patients who had developed UGB.
Copyright © 2013 S. Karger AG, Basel.
Similar articles
-
Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.Am J Gastroenterol. 2012 Jul;107(7):1043-50. doi: 10.1038/ajg.2012.113. Epub 2012 Jun 19. Am J Gastroenterol. 2012. PMID: 22710579 Clinical Trial.
-
Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.Hepatogastroenterology. 2000 Mar-Apr;47(32):473-7. Hepatogastroenterology. 2000. PMID: 10791216 Clinical Trial.
-
Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.J Gastroenterol Hepatol. 2012 Aug;27(8):1329-35. doi: 10.1111/j.1440-1746.2012.07186.x. J Gastroenterol Hepatol. 2012. PMID: 22606978 Clinical Trial.
-
Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding.Rev Assoc Med Bras (1992). 2016 May-Jun;62(3):243-7. doi: 10.1590/1806-9282.62.03.243. Rev Assoc Med Bras (1992). 2016. PMID: 27310548
-
Update on management of patients with overt hepatic encephalopathy.Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Hosp Pract (1995). 2013. PMID: 23948621 Review.
Cited by
-
Hyperammonemic coma after craniotomy: Hepatic encephalopathy from upper gastrointestinal hemorrhage or valproate side effect?: Case report and literature review.Medicine (Baltimore). 2017 Apr;96(15):e6588. doi: 10.1097/MD.0000000000006588. Medicine (Baltimore). 2017. PMID: 28403092 Free PMC article. Review.
-
Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?J Clin Med. 2023 Jun 7;12(12):3903. doi: 10.3390/jcm12123903. J Clin Med. 2023. PMID: 37373598 Free PMC article.
-
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst Rev. 2016 May 6;2016(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Cochrane Database Syst Rev. 2016. PMID: 27153247 Free PMC article.
-
Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution.J Clin Med. 2023 Feb 2;12(3):1187. doi: 10.3390/jcm12031187. J Clin Med. 2023. PMID: 36769836 Free PMC article. Review.
-
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.Can J Gastroenterol Hepatol. 2018 Jul 10;2018:3015891. doi: 10.1155/2018/3015891. eCollection 2018. Can J Gastroenterol Hepatol. 2018. PMID: 30079329 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous